Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium

CC Konkankit, SC Marker, KM Knopf, JJ Wilson - Dalton Transactions, 2018 - pubs.rsc.org
The clinical success of the platinum-based chemotherapeutic agents has prompted the
investigation of coordination and organometallic complexes of alternative metal centers for …

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

S Fulda, KM Debatin - Oncogene, 2006 - nature.com
Apoptosis or programmed cell death is a key regulator of physiological growth control and
regulation of tissue homeostasis. One of the most important advances in cancer research in …

Polymeric micelles: nanocarriers for cancer-targeted drug delivery

Y Zhang, Y Huang, S Li - Aaps Pharmscitech, 2014 - Springer
Polymeric micelles represent an effective delivery system for poorly water-soluble anticancer
drugs. With small size (10–100 nm) and hydrophilic shell of PEG, polymeric micelles exhibit …

Neddylation of PTEN regulates its nuclear import and promotes tumor development

P Xie, Z Peng, Y Chen, H Li, M Du, Y Tan, X Zhang… - Cell research, 2021 - nature.com
PTEN tumor suppressor opposes the PI3K/Akt signaling pathway in the cytoplasm and
maintains chromosomal integrity in the nucleus. Nucleus–cytoplasm shuttling of PTEN is …

Strategies of targeting CK2 in drug discovery: challenges, opportunities, and emerging prospects

Y Chen, Y Wang, J Wang, Z Zhou, S Cao… - Journal of Medicinal …, 2023 - ACS Publications
CK2 (casein kinase 2) is a serine/threonine protein kinase that is ubiquitous in eukaryotic
cells and plays important roles in a variety of cellular functions, including cell growth …

Promoting apoptosis as a strategy for cancer drug discovery

SW Fesik - Nature Reviews Cancer, 2005 - nature.com
Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that
restore the normal apoptotic pathways have the potential for effectively treating cancers that …

Oncogenic protein interfaces: small molecules, big challenges

TL Nero, CJ Morton, JK Holien, J Wielens… - Nature Reviews …, 2014 - nature.com
Historically, targeting protein–protein interactions with small molecules was not thought
possible because the corresponding interfaces were considered mostly flat and featureless …

X-linked inhibitor of apoptosis protein–a critical death resistance regulator and therapeutic target for personalized cancer therapy

P Obexer, MJ Ausserlechner - Frontiers in oncology, 2014 - frontiersin.org
Defects in apoptosis regulation are one main cause of cancer development and may result
from overexpression of anti-apoptotic proteins such as inhibitor of apoptosis proteins (IAPs) …

Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases:“reverse pharmacology” and “bedside to bench” approach

B B. Aggarwal, S Prasad, S Reuter… - Current drug …, 2011 - benthamdirect.com
Inflammation, although first characterized by Cornelius Celsus, a physician in first Century
Rome, it was Rudolf Virchow, a German physician in nineteenth century who suggested a …

Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization

Z Nikolovska-Coleska, R Wang, X Fang, H Pan… - Analytical …, 2004 - Elsevier
The X-linked inhibitor of apoptosis protein (XIAP) is a potent cellular inhibitor of apoptosis.
Designing small-molecule inhibitors that target the BIR3 domain of XIAP, where …